Organogenesis Holdings Inc. (NASDAQ:ORGO) Shares Bought by State Street Corp

State Street Corp increased its position in Organogenesis Holdings Inc. (NASDAQ:ORGO) by 0.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,459,767 shares of the company’s stock after buying an additional 9,090 shares during the period. State Street Corp owned about 1.10% of Organogenesis worth $4,175,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Captrust Financial Advisors purchased a new stake in Organogenesis in the 3rd quarter worth approximately $36,000. Delap Wealth Advisory LLC purchased a new stake in shares of Organogenesis in the second quarter valued at $40,000. Intech Investment Management LLC acquired a new position in Organogenesis in the third quarter valued at $43,000. Allspring Global Investments Holdings LLC lifted its position in Organogenesis by 4,989.9% during the second quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock worth $44,000 after buying an additional 15,369 shares during the period. Finally, Pallas Capital Advisors LLC lifted its position in Organogenesis by 70.8% during the third quarter. Pallas Capital Advisors LLC now owns 21,823 shares of the company’s stock worth $63,000 after buying an additional 9,048 shares during the period. Hedge funds and other institutional investors own 49.57% of the company’s stock.

Organogenesis Trading Down 2.7 %

NASDAQ ORGO opened at $3.19 on Monday. The company has a market cap of $401.07 million, a P/E ratio of -53.17 and a beta of 1.73. Organogenesis Holdings Inc. has a 12 month low of $2.16 and a 12 month high of $4.70. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74. The company has a 50-day moving average of $3.46 and a 200-day moving average of $3.04.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.11. The firm had revenue of $115.18 million during the quarter, compared to analyst estimates of $109.59 million. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. During the same quarter in the prior year, the business posted $0.02 earnings per share. As a group, equities analysts predict that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current year.

Insider Activity at Organogenesis

In related news, CEO Gary S. Gillheeney sold 55,615 shares of the stock in a transaction on Friday, December 13th. The stock was sold at an average price of $3.36, for a total value of $186,866.40. Following the completion of the sale, the chief executive officer now directly owns 3,044,779 shares in the company, valued at approximately $10,230,457.44. This represents a 1.79 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last 90 days, insiders have sold 278,116 shares of company stock worth $991,190. 36.90% of the stock is owned by insiders.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.